bullish

Takeda Pharmaceutical (4502 JP): Beat-And-Raise Q2 Amid Strong Performance of New Drugs

442 Views03 Nov 2024 00:54
​Takeda Pharmaceutical beats Q2FY25 estimates with strong growth from Growth and Launch Products. The company is raising FY25 guidance despite expected H2FY25 challenges.
What is covered in the Full Insight:
  • Q2FY25 Financial Performance
  • FY25 Guidance Revision
  • Performance of Key Drugs
  • New Product Launches
  • Pipeline Developments
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
x